Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Compass Therapeutics, Inc. OTC Markets

Equities

CMPX

US20454B1044

Delayed OTC Markets
Other stock markets
 19:59:57 03/11/2021 GMT 		5-day change 1st Jan Change
3.55 USD -10.80% Intraday chart for Compass Therapeutics, Inc. +32.67% -.--%
05-28 Compass Therapeutics Appoints Thomas Schuetz as CEO MT
05-28 Compass Therapeutics, Inc. Announces CEO Changes CI

Evolution of the average Target Price on Compass Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0de59c31eacb06ed2582c56730f.Ok4rtzpM6Yv1qRRwfWClp_RcFoCUoU5roiDSwUYE0lY.XzhewVkkgcyPwGQSPzPVwq1vUO3ilHcT41OBhwd2jTJLKW3DCHy7s6b5XQ~e3c0b709bf39c5f9d28a2def0047cd95

Analyst Recommendations on Compass Therapeutics, Inc.

Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.41 USD
Average target price
9 USD
Spread / Average Target
+538.30%
High Price Target
11 USD
Spread / Highest target
+680.14%
Low Price Target
7 USD
Spread / Lowest Target
+396.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Compass Therapeutics, Inc.

Jefferies & Co.
Stifel Nicolaus
EF Hutton
Raymond James
HC Wainwright
SVB Leerink
Ladenburg Thalmann
B. Riley
Wedbush
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. CMPX Stock
  5. Consensus Compass Therapeutics, Inc.